Jack A. Grebb, MD
Affiliations: | Associate Professor of Psychiatry | New York University, New York, NY, United States | |
Associate Professor of Neuroscience | Rockefeller Institute for Medical Research, New York, NY, United States | ||
Medical School | University of Vermont, Burlington, VT, United States | ||
Psychiatry | University of California, San Francisco, San Francisco, CA | ||
1992 | Post-Doctoral Fellow National Institute of Mental Health | National Institutes of Health, Bethesda, MD | |
1992-1993 | Clinical Research - Psychiatry | Abbott Laboratories, Irving, TX, United States | |
1993-2003 | Clinical Research - Psychiatry and Neurology | Janssen Pharmaceutical Companies | |
2003-2007 | Clinical Research - Psychiatry | Bristol-Myer Squibb |
Area:
Schizophrenia, substance abuse and signal transductionGoogle:
"Jack Grebb"Bio:
Jack A. Grebb, M.D. (1953-2007)
Jack was psychiatrist who worked for 15 years leading the development of various psychiatric, neurologic, and pain drugs at pharmaceutical companies. He obtained his B.A. and M.D. degree's from the University of Vermont. Dr. Grebb completed his psychiatric internship and residency at the University of California at San Francisco, after which he completed a research fellowship at the National Institute of Mental Health in Washington, DC. Following his training, Dr. Grebb held joint academic appointments at the Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University, and in the Department of Psychiatry at New York University Medical Center. His major areas of research interest were schizophrenia, substance abuse, and the study of signal transduction in the nervous system. In 1992, Dr. Grebb started work at Abbott Laboratories, and subsequently moved to Johnson & Johnson, and then BristolMyers Squibb Company, at which companies he was in charge of the development of a number of major pharmaceuticals used in the treatment of psychiatric, neurological, and pain disorders. In addition to his research activities, Dr. Grebb was a contributing editor for the Kaplan & Sadocks Comprehensive Textbook of Psychiatry, a leading textbook in the field. His extensive contributions centered on the areas of basic neuroscience and clinical psychopharmacology. Dr. Grebb also maintained his lifelong interest as a performer of classical organ music. Dr. Grebb started playing the organ when he was five years old, and held numerous church positions throughout his early training. Following his medical training, Dr. Grebb continued his music career by presenting benefit concerts in the US and Europe for a wide range of social and medical causes, including groups focused on the support of individuals and families with major mental illnesses.
(Show less)
Mean distance: 106866
Collaborators
Sign in to add collaboratorPaul Greengard | collaborator | Rockerfeller University | |
Paul A.J. Janssen | collaborator | 1993-2003 | Janssen Pharmaceutical Companies |
Todd D. McIntyre | collaborator | 1993-2003 | Janssen Research Foundation |
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Coric V, Feldman HH, Oren DA, et al. (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depression and Anxiety. 27: 417-25 |
Crowley WF, Sherwood L, Salber P, et al. (2004) Clinical research in the United States at a crossroads: proposal for a novel public-private partnership to establish a national clinical research enterprise. Jama. 291: 1120-6 |
Sung NS, Crowley WF, Genel M, et al. (2003) Central challenges facing the national clinical research enterprise. Jama. 289: 1278-87 |
Gheuens J, Grebb JA. (1998) Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders". Journal of Clinical Psychopharmacology. 18: 176-9 |
Schooler NR, Tollefson GD, Tran PV, et al. (1998) Comments on article by Tran and colleagues, 'double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders' (Multiple letters) [4] Journal of Clinical Psychopharmacology. 18: 174-179 |
Gutierrez-Esteinou R, Grebb JA. (1997) Risperidone: an analysis of the first three years in general use. International Clinical Psychopharmacology. 12: S3-10 |
Grebb JA. (1997) XX Meeting of the Collegium Internationale Psychopharmacologicum (CIMP) and the X World Congress of Psychiatry (WCP): Introduction International Clinical Psychopharmacology. 12: S1 |
Nordstedt C, Gandy SE, Alafuzoff I, et al. (1991) Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment. Proceedings of the National Academy of Sciences of the United States of America. 88: 8910-4 |
Gandy SE, Grebb JA, Rosen N, et al. (1990) General assay for phosphoproteins in cerebrospinal fluid: a candidate marker for paraneoplastic cerebellar degeneration. Annals of Neurology. 28: 829-33 |
Grebb JA, Girault JA, Ehrlich M, et al. (1990) Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. Journal of Neurochemistry. 55: 204-7 |